Toxic epidermal necrolysis developed following sintilimab administration in one patient.
Monitoring for skin reactions is critical during immune checkpoint inhibitor therapy.
Case emphasizes the serious risks in advanced lung squamous cell carcinoma treatment with sintilimab.
Immediate intervention may be necessary to address severe adverse effects associated with therapy.
Abstract
This report highlights the potential for Sintilimab to induce life-threatening TEN, emphasizing the need for vigilant monitoring and prompt intervention during ICIs therapy.